Ultomiris

  • Name:

    Ultomiris

  • Company:
    info
  • Active Ingredients:

    Ravulizumab

  • Legal Category:

    Product subject to restricted prescription (C)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/07/19

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 12/7/2019
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

Alexion Pharma UK Ltd

Alexion Pharma UK Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Kanuma Active Ingredients Sebelipase alfa
Medicine Name Soliris Active Ingredients Eculizumab
Medicine Name Strensiq 100mg/ml Active Ingredients Asfotase alfa
Medicine Name Strensiq 40mg/ml Active Ingredients Asfotase alfa
Medicine Name Ultomiris Active Ingredients Ravulizumab
1 - 0 of 5 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 24 February 2020 Ed-HCP

Reasons for updating

  • Add New Doc

Updated on 24 February 2020 Ed-HCP

Reasons for updating

  • Add New Doc

Updated on 24 February 2020 Ed-Both

Reasons for updating

  • Add New Doc

Updated on 12 July 2019 PIL

Reasons for updating

  • New PIL for new product

Updated on 12 July 2019 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

New medcinal product Ultomiris:   ravulizumab 300mg concentrate for solution for infusion.